<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36314539</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of medicine</Title><ISOAbbreviation>Ann Med</ISOAbbreviation></Journal><ArticleTitle>Profiling non-coding RNA expression in cerebrospinal fluid of amyotrophic lateral sclerosis patients.</ArticleTitle><Pagination><StartPage>3069</StartPage><EndPage>3078</EndPage><MedlinePgn>3069-3078</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2138530</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Objective biomarkers for the fatal neurodegenerative disease amyotrophic lateral sclerosis or motor neuron disease (ALS/MND) are critical for diagnosis, drug development, clinical trials, and insight into disease pathology. Key candidates for biomarkers present in biofluids include non-coding RNA (ncRNA) transcripts including microRNA, piwi-interacting RNA and transfer RNA. To determine if the central nervous system was the source of the dysregulated ncRNA biomarkers we previously observed in serum, we sought to identify dysregulated ncRNA candidates in cerebrospinal fluid (CSF) which may provide new insight into the disease pathology.</AbstractText><AbstractText Label="METHODS AND MATERIALS">Small RNA sequencing (RNA-seq) was undertaken on CSF samples from healthy controls (<i>n</i>&#x2009;=&#x2009;18), disease mimics (<i>n</i>&#x2009;=&#x2009;8), and ALS patients (<i>n</i>&#x2009;=&#x2009;40) in our Oxford Study for Biomarkers of ALS cohort, with RT-qPCR used to confirm their dysregulation.</AbstractText><AbstractText Label="RESULTS">We found a range of ncRNA that were dysregulated in the RNA-seq screen, but these failed to be validated or detected in some cases using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Additionally, our previously identified serum ncRNA biomarker showed no change in CSF or correlation to serum.</AbstractText><AbstractText Label="CONCLUSIONS">This study suggests the CSF may not be the source of dysregulated ncRNA in the serum and highlights the difficulty in identifying ncRNA in CSF as biomarkers for ALS.KEY MESSAGESIn this current study, we investigated the expression of non-coding RNA transcripts in the cerebrospinal fluid of ALS patients compared to healthy controls.RNA-seq identified dysregulated non-coding RNA transcripts, but these were not validated with RT-qPCR.We conclude that cerebrospinal fluid is not a suitable source of diagnostic biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joilin</LastName><ForeName>Greig</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5827-6382</Identifier><AffiliationInfo><Affiliation>School of Life Sciences, University of Sussex, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-1063-3277</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leigh</LastName><ForeName>P Nigel</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Brighton and Sussex Medical School, University of Sussex, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newbury</LastName><ForeName>Sarah F</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0002-1863-3258</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Sussex, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hafezparast</LastName><ForeName>Majid</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5262-7150</Identifier><AffiliationInfo><Affiliation>School of Life Sciences, University of Sussex, Brighton, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K01014X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>HAFEZPARAST/APR15/836-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>HAFEZPARAST/APR18/861-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T006927/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BB/P021042/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med</MedlineTA><NlmUniqueID>8906388</NlmUniqueID><ISSNLinking>0785-3890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">RNA-seq</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">non-coding RNA</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>31</Day><Hour>7</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36314539</ArticleId><ArticleId IdType="pmc">PMC9629092</ArticleId><ArticleId IdType="doi">10.1080/07853890.2022.2138530</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S, Al Khleifat A, Al-Chalabi A.. What causes amyotrophic lateral sclerosis? F1000Res. 2017;6:371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373425</ArticleId><ArticleId IdType="pubmed">28408982</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Ba Y, Ma L, et al. . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">18766170</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin XF, Wu N, Wang L, et al. . Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing Central nervous system diseases. Cell Mol Neurobiol. 2013;33(5):601&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">23633081</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G, Leigh PN, Newbury SF, et al. . An overview of microRNAs as biomarkers of ALS. Front Neurol. 2019;10:186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416171</ArticleId><ArticleId IdType="pubmed">30899244</ArticleId></ArticleIdList></Reference><Reference><Citation>de Andrade HM, de Albuquerque M, Avansini SHdSRC, et al. . MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J Neurol Sci. 2016;368:19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">27538595</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G, Gray E, Thompson AG, et al. . Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis. Brain Commun. 2020;2(1):fcaa053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7329382</ArticleId><ArticleId IdType="pubmed">32613197</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen JM, Manzano R, Olivan S, et al. . MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One. 2014;9(2):e89065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930686</ArticleId><ArticleId IdType="pubmed">24586506</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Goodall EF, Milo M, et al. . Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. 2017;55:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosaka N, Iguchi H, Yoshioka Y, et al. . Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285(23):17442&#x2013;17452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878508</ArticleId><ArticleId IdType="pubmed">20353945</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda A, Yan IK, Foye C, et al. . MicroRNAs as paracrine signaling mediators in cancers and metabolic diseases. Best Pract Res Clin Endocrinol Metab. 2016;30(5):577&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5147504</ArticleId><ArticleId IdType="pubmed">27923452</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Heman-Ackah SM, et al. . 2016. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat Rev Neurol. 12:346&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">27174238</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Mager I, et al. . UFLC-derived CSF extracellular vesicle origin and proteome. Proteomics. 2018;18(24):e1800257.</Citation><ArticleIdList><ArticleId IdType="pubmed">30411858</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Pol J, Gosselet F, Duban-Deweer S, et al. . Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells. 2020;9(4):851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226770</ArticleId><ArticleId IdType="pubmed">32244730</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Wyles M, Heath PR, et al. . Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. Front Neurosci. 2017;11:731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767269</ArticleId><ArticleId IdType="pubmed">29375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):3.</Citation></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M, et al. . Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S.. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen CL, Jensen JL, Orntoft TF.. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and Colon cancer data sets. Cancer Res. 2004;64(15):5245&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289330</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AH, Valdez G, Moresi V, et al. . MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009;326(5959):1549&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796560</ArticleId><ArticleId IdType="pubmed">20007902</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaka Y, Kishi S, Aoki Y, et al. . Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med. 2014;19(6):452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4235845</ArticleId><ArticleId IdType="pubmed">25150707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Wang J, He J, et al. . Serum miRNAs miR-23a, 206, and 499 as potential biomarkers for skeletal muscle atrophy. Biomed Res Int. 2017;2017:8361237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682897</ArticleId><ArticleId IdType="pubmed">29214178</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcianna A, Myszczynska MA, Castelli LM, et al. . Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine. 2019;40:626&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413467</ArticleId><ArticleId IdType="pubmed">30711519</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Messina L, Gutierrez-Vazquez C, Rivas-Garcia E, et al. . Immunomodulatory role of microRNAs transferred by extracellular vesicles. Biol Cell. 2015;107(3):61&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010100</ArticleId><ArticleId IdType="pubmed">25564937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar K, Shigematsu M, Sharbati S, et al. . Infection-induced 5'-half molecules of tRNAHisGUG activate Toll-like receptor 7. PLoS Biol. 2020;18(12):e3000982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745994</ArticleId><ArticleId IdType="pubmed">33332353</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada I, Gabrielli M, Turola E, et al. . Glia-to-neuron transfer of miRNAs via extracellular vesicles: a new mechanism underlying inflammation-induced synaptic alterations. Acta Neuropathol. 2018;135(4):529&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5978931</ArticleId><ArticleId IdType="pubmed">29302779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren W, Hou J, Yang C, et al. . Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. J Exp Clin Cancer Res. 2019;38(1):62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367822</ArticleId><ArticleId IdType="pubmed">30736829</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>